Mad Hedge Biotech and Healthcare Letter February 17, 2026 Fiat Lux Featured Trade: (A SURVIVOR OF THE GLP-1 MASSACRE) (VKTX), (NVO), (LLY)
Tag Archives: (NVO)
The GLP-1 stock massacre of 2025 was brutal, indiscriminate, and thoroughly predictable. Viking Therapeutics (VKTX) got caught in the crossfire, dropping from its peak alongside every other obesity drug hopeful when the market decided a price war was imminent. I watched the selling cascade through the sector like an avalanche, taking down pre-revenue biotechs and […]
Mad Hedge Biotech and Healthcare Letter February 3, 2026 Fiat Lux Featured Trade: (THE PRICE OF ADMISSION) (LLY), (NVO)
Mad Hedge Biotech and Healthcare Letter January 29, 2026 Fiat Lux Featured Trade: (THIS THIRD WHEEL IS RIDING SHOTGUN) (AMGN), (NVO), (LLY)
Obesity is a $100 billion market in the making, and the market’s already crowned two kings: Eli Lilly (LLY) and Novo Nordisk (NVO). Which makes Amgen (AMGN) the quiet third, aka the biotech equivalent of the third man in a two-man race. But here’s the thing – MariTide isn’t just a me-too molecule. It’s potentially […]
Mad Hedge Biotech and Healthcare Letter January 27, 2026 Fiat Lux Featured Trade: (THE ASPIRIN STANDARD) (REGN), (BAYRY), (RHHBY), (SNY), (NVO), (LLY)
In 1899, Bayer (BAYRY) patented acetylsalicylic acid – what we now call aspirin. This “miracle drug” then became the cornerstone of one of the most powerful pharmaceutical empires the world had ever seen. Unfortunately for Bayer, by 1917, they had to give up the patent as part of World War I reparations. Poof. Gone. That’s […]
There is a predictable arc to every great pharmaceutical story. First comes disbelief, then euphoria, then inevitability, and finally punishment for having believed too much of your own press. Novo Nordisk (NVO) reached that final phase in 2025, not because semaglutide stopped working, but because investors forgot how brutally unforgiving this business becomes once expectations […]
Mad Hedge Biotech and Healthcare Letter December 23, 2025 Fiat Lux Featured Trade: (CLIMBING THE CLIFF IN REVERSE) (REGN), (AMGN), (MRK), (BMY), (NVO), (LLY)
A few months ago, I found myself sipping flat champagne on a Gulfstream out of Aspen, locked in one of those altitude-fueled biotech postmortems. On my left: a hedge fund manager freshly out of his biotech positions after a bruising year. On my right: a dermatologist who moonlights as a GLP‑1 evangelist. Regeneron (REGN) came […]